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Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a
fatal motor neuron disorder. It results in progressive degeneration and death of upper
and lower motor neurons, protein aggregation, severe muscle atrophy and respiratory
insufficiency. Median survival with ALS is between 2 and 5 years from the onset of
symptoms. ALS manifests as either familial ALS (FALS) (∼10% of cases) or sporadic ALS
(SALS), (∼90% of cases). Mutations in the copper/zinc (CuZn) superoxide dismutase
(SOD1) gene account for ∼20% of FALS cases and the mutant SOD1 mouse model
has been used extensively to help understand the ALS pathology. As the precise
mechanisms causing ALS are not well understood there is presently no cure. Recent
evidence suggests that motor neuron degradation may involve a cell non-autonomous
phenomenon involving numerous cell types within various tissues. Skeletal muscle is
now considered as an important tissue involved in the pathogenesis of ALS by activating
a retrograde signaling cascade that degrades motor neurons. Skeletal muscle heath
and function are regulated by numerous factors including satellite cells, mitochondria
and microRNAs. Studies demonstrate that in ALS these factors show various levels
of dysregulation within the skeletal muscle. This review provides an overview of their
dysregulation in various ALS models as well as how they may contribute individually
and/or synergistically to the ALS pathogenesis.
Keywords: skeletal muscle, amyotrophic lateral sclerosis, satellite cell, mitochondria, miRNA, neuromuscular
junction
PATHOPHYSIOLOGY OF ALS
In ALS the cause of motor neuron degeneration remains equivocal. However, motor neuron
death is a leading candidate (Kennel et al., 1996). Numerous mechanisms are suggested to
be involved in ALS. Therefore, it is considered a “multisystemic” disease in which changes in
structural, physiological, and metabolic parameters in different cell types, may act mutually and
synergistically, to contribute to disease on set and severity (Cozzolino et al., 2008; Musaro, 2013).
Several factors have been investigated as possible contributors to motor neuron death, including
excitotoxicity, oxidative stress, deficits in axonal transport, neurofilament aggregation, protein
aggregation, involvement of non-neuronal cells, mitochondrial dysfunction and the dysregulation
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in microRNA processing and expression. The motor neuron
degeneration observed in ALS is a cell non-autonomous
phenomenon involving numerous cell types. Evidence that ALS
pathology starts at the neuromuscular junction (NMJ) rather
than the motor neuron (Fischer et al., 2004; Jokic et al.,
2006; Dupuis et al., 2009) has led to ALS being recognized
and reviewed as a distal axonopathy, whereby skeletal muscle
contributes to a retrograde signaling cascade that degrades
motor neurons (Dupuis et al., 2009; Dadon-Nachum et al.,
2011; Boyer et al., 2013; Moloney et al., 2014). Disturbances
in several mechanisms important for maintaining healthy
skeletal muscle mass and function, such as satellite cell activity,
mitochondrial biogenesis and miRNA regulation, are observed
in ALS. Interestingly, these factors may act synergistically to
maintain healthy skeletal muscle andmay influence NMJ number
and activity. This review highlights our understanding of how
satellite cell activation, mitochondrial function and miRNAs may
impact ALS pathogenies with a focus on skeletal muscle and NMJ
degeneration (Figure 1 and Table 1).
FIGURE 1 | Potential crosstalk between SC, mitochondria and miRNAs to influence NMJ and skeletal muscle health in ALS. Green arrows indicate
regulatory relationships between molecules, as well as between molecules and structures. A reduction in Pax7 and MyoD may contribute to the attenuation in SC
activation and number. SCs not only maintain skeletal muscle fiber size and function, but those located near the NMJ also play role in maintaining NMJ stability.
Similarly, downregulation of molecular targets including PGC-1α, ERRα, and NRF may impair mitochondrial biogenesis and function. As mitochondria play role in
maintaining calcium homeostasis and muscle repair, their dysregulation may also contribute to skeletal muscle and NMJ deterioration. Perturbations in miRNAs, such
as miR-206, may negatively impact regenerative capacity and NMJ stability via their control over MRFs (myogenic regulatory factors) and HDAC4 transcription.
Additionally, the upregulation of miRNA-23a may negatively impact the PGC-1α signaling cascade and mitochondrial function; as consequence indirectly contributing
to impaired skeletal muscle repair and NMJ stability.
THE ROLE OF SATELLITE CELLS IN ALS
PATHOLOGY
Overexpressing the mutant SOD1 protein specifically in healthy
skeletal muscle induces an ALS phenotype and a degradation
of motor neurons (Dobrowolny et al., 2008; Wong and Martin,
2010), supporting a direct role of skeletal muscle in disease
progression. However, the mechanisms within the muscle that
contribute to the initial loss of muscle mass and eventual
degeneration of the NMJ and motor neurons are unknown.
Skeletal muscle repairs itself via the well-coordinated process of
myogenesis that relies on efficient satellite cell (SC) activation,
proliferation, fusion, and differentiation (Mauro, 1961). Under
basal conditions SCs are quiescent, becoming activated in
response to acute injury, muscle denervation or exercise stimuli.
Once activated, SC’s proliferate, differentiate into myoblasts and
fuse with existing myofibres resulting in muscle fiber repair
and/or growth. When SCs are mitotically quiescent, they express
the myogenic regulatory factor (MRF) family member, paired
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box 7 transcription factor, Pax7 (Seale et al., 2000) as well
the adhesion molecule M-cadherin (Irintchev et al., 1994),
the hematopoietic progenitor cell antigen, CD34 (Beauchamp
et al., 2000) and another MRF, myogenic transcription factor-
5, Myf5 (Tajbakhsh et al., 1997). Upon activation, and when
the cells are no longer in the quiescent state, SCs also express
the MRF, myogenic differentiation 1 (MyoD) (Fuchtbauer and
Westphal, 1992), however CD34 is not expressed (Zammit
et al., 2006). Therefore, co-expression of both MRF family
members, Pax7 and MyoD, is an indication that the cells have
moved from the quiescent to the active state. As the activated
cells begin to proliferate, Pax7 is downregulated, while MyoD
and/or Myf5 expression remains. During differentiation, another
MRF, myogenin (MyoG; Myf4) is expressed and is essential
for SC differentiation into multinucleated myotubes. As such,
myogenin is used as a marker of the onset of myogenic
differentiation (Fuchtbauer and Westphal, 1992). The myogenic
capacity of skeletal muscle from either patients with ALS or
rodent models of human ALS has not been extensively studied so
our understanding of howmyogenic perturbations contributes to
disease on-set and progression is limited.
Satellite cell cultures obtained from ALS patient biopsies have
been observed to proliferate similarly to cultures obtained from
healthy muscle, however, with a morphology that resembles
senescent cells (Pradat et al., 2011). In contrast, another study has
observed that ALS patient-derived myoblast cultures proliferate
faster than control cultures (Scaramozza et al., 2014). Compared
with control cultures, the ALS patient-derived myoblast cultures
had significantly more MyoD mRNA, but similar Pax7 mRNA,
levels suggesting that the ALS patient-derived myoblast cultures
were in a more committed state (Scaramozza et al., 2014).
These myogenic markers were not measured by Pradat et al.
(2011). The different observations made by Pradat et al. (2011)
and Scaramozza et al. (2014), when comparing ALS-derived
myoblast proliferation with control myoblast proliferation, may
be attributed to different muscle samples biopsied, disease stage
when the biopsies were taken as well as patient age. However,
both of these studies observed that ALS-derived myoblasts are
unable to fully differentiate into myotubes (Pradat et al., 2011;
Scaramozza et al., 2014). Myotubes from ALS patients have
a lower levels of fast, slow and neonatal myosin heavy chain
(MHC) proteins when compared to control myotubes (Pradat
et al., 2011), as well as decreased levels of the MyoG protein
(Scaramozza et al., 2014). Muscle biopsies from ALS patients and
healthy control have the same absolute number of satellite cells,
as quantified by Pax7 staining. However, very few of these Pax7-
positive nuclei are positive for MyoD, but surprisingly, positive
for MyoG (Pradat et al., 2011). These observations in muscle
cell culture and muscle tissue suggest that SCs appear to be
moving into a senescent state and that there is a perturbation
in the signals required for efficient and complete myogenesis.
As a result, the skeletal muscle is unable to effectively repair
and regenerate, resulting in severe muscle atrophy and weakness.
However, the mechanisms contributing to these changes have
not been precisely elucidated. Such knowledge is required before
targeted therapies aimed at restoring myogenic capacity can
be tested. Developing SC cultures from ALS patients is very
challenging. Therefore, information relating to the impaired
myogenic capacity in muscle cultures and muscle tissue has
been obtained from a very small number of ALS patients. More
studies are required to confirm and add to this knowledge
base.
In the mutant SOD1G93A (glycine to alanine mutation at
position 93) ALS mouse impaired SCs number and activation
is dependent on disease stage and muscle fiber type (Manzano
et al., 2012). SC number is reduced in both slow (soleus)
and fast (extensor digitorum longus; EDL) muscle fibers of
SOD1G93A mice compared to non-transgenic mice at the early
presymptomatic stage (p40). However, fiber type differences
appear with disease progression. At late presymptomatic stage
(p60) the soleus muscle presented with an increased number
of SCs, while there is no difference in the EDL muscle. At
symptomatic stage (p90) the soleus muscle presented with a
decreased number of SCs, while there was an increase in the EDL
muscle. Finally, at end stage (p120), the SC count resembled that
previously observed at p60, with an increased number of SCs in
the soleus and no difference in the EDL muscle. The percentage
of myofibre-associated SCs co-expressing Pax7 and MYOD was
used as an indication of SC activation. At early presymptomatic
stage (p40) no difference in SC activation was observed, however
at p60 there was an increase and a tendency for a decrease in the
soleus and EDL muscle, respectively (Manzano et al., 2012). At
symptomatic stage (p90) there was an increase in the number
of active SC in both fiber types, however this returned to the
same levels as the non-transgenic mice at end stage (p120).
These temporal and muscle-specific changes in SC number, and
potential SC activation, are most likely indicative of an attempted
adaptive response to regenerate the muscle due to toxic insults
induced by mitochondrial dysfunction, oxidative stress, protein
aggregation and denervation. As observed in muscle from ALS
patients, an early dysregulation in MRFs may contribute to the
alteration in SC number and SC activation. In presymptomatic
(p60) mice Pax7 and Myog mRNA and MYF5 protein were
increased (Manzano et al., 2013). However, the upregulation of
the Pax7 protein, as well as the mRNA levels of other MRFs,
including Myf5, Myod1, and Myog, was not observed until mice
were symptomatic (p90) (Manzano et al., 2013). While the
changes in these mRNA levels were still visible at end stage
(p120), there was no upregulation of the corresponding protein
levels (Manzano et al., 2013).
While it is well established that skeletal muscle regeneration
and size is significantly influenced by SC number and efficient
activation of the various myogenic stages (Mauro, 1961),
recent evidence has shown that SC’s also play a role in
maintaining NMJ health (Liu et al., 2015). Following nerve
injury, SC’s become active and divide during NMJ regeneration.
SC depletion causes muscle fiber atrophy, increased connective
tissue between the myofibres and impaired myofibre/NMJ
connectivity. Interestingly, there was an increase in SC activity
and fusion to existing myofibres in close proximity to where
NMJ regeneration was occurring. As such, SC depletion resulted
in inefficient reinnervation of the NMJ, impaired post-synaptic
morphology and reductions in post-synaptic myonuclei. While
the occurrence of this phenomenon has not been investigated
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in models of human ALS, it demonstrates the potential
synergy between SC’s and the NMJ. This further highlights the
importance of maintaining optimal myogenesis in ALS.
SKELETAL MUSCLE MITOCHONDRIAL
DYSFUNCTION IN ALS
In SOD1G93A ALS mice motor neuron mitochondrial
degeneration precedes paralysis (Kong and Xu, 1998). As such,
impaired mitochondrial function and death is considered an
important component in ALS pathogenesis (Menzies et al., 2002).
It has been well established in ALS that SOD1 mutations cause
an accumulation of aggregates inside mitochondria, fragmented
mitochondrial networks and mitochondrial depolarization and
this has been reviewed extensively (Dupuis et al., 2004; Faes
and Callewaert, 2011; Bozzo et al., 2016). In skeletal muscle
of ALS patients and mice, impaired mitochondrial function is
well known and reviewed previously (Appel, 2006; Shi et al.,
2010). This is indicated by NADH:CoQ oxidoreductase and
cytochrome c oxidase (COX) deficiency, reduced mitochondrial
DNA and reduced levels of mitochondria Mn-SOD (Wiedemann
et al., 1998; Vielhaber et al., 2000).
Abnormal skeletal muscle mitochondrial dynamics is also
observed in presymptomatic SOD1G93A ALS mice (Luo et al.,
2013). As the disease progresses in SOD1G93A ALS mice,
SOD1 activity increases in skeletal muscle, but not in motor
neurons, (Leclerc et al., 2001) suggesting that skeletal muscle
is an important player in disease progression and severity.
Overexpressing mutant SOD1G93A in skeletal muscle of healthy
mice produces similar perturbations in mitochondrial dynamics
that are observed in ALS SOD1G93A mice (Luo et al., 2013).
This demonstrates that the skeletal muscle SOD1 mutation is
sufficient to cause an ALS-like muscle pathology independent of
any initial motor neuron degeneration and further supports the
involvement of skeletal muscle in ALS pathogenesis.
Skeletal muscle mitochondria from SOD1 ALS mice
also present with altered bioenergetics. Maximal oxygen
consumption and ADP stimulated oxidative phosphorylation
are lower in the soleus, but not the extensor digitorum longus
(EDL) or diaphragm muscles, from 130 day old SOD1G93A ALS
mice, when compared with aged-matched controls (Leclerc
et al., 2001). In the hindlimb muscles from SOD1G86R ALS mice
(glycine to arginine mutation at position 86), when compared
with control mice, respiratory control ratio (ratio between state
3 and state 2 respiration) is decreased (Dupuis et al., 2003).
This occurred without an associated reduction in COX activity,
suggesting increased mitochondrial uncoupling. In parallel with
this was the observation of lower ATP levels in the gastrocnemius
muscle of the SOD1G86R ALS mice at ages, 75, 90, and 105 days
of age. Improvements in quadriceps muscle mitochondrial
bioenergetics (in addition to spinal cord) in 90 day old
SOD1G93A ALS mice has been achieved by oral administration
of the mitochondrial-targeted antioxidant [10-(4,5-dimethoxy-
2-methyl-3,6-dioxo-1,4-cyclohexadien- 1-yl)decyl]triphenyl-,
methanesulfonate (MitoQ). This intervention slowed the decline
in mitochondrial respiratory function, improved NMJ stability,
grip strength and prolonged survival by ∼7 days in both male
and female mice (Miquel et al., 2014).
In terms of potential molecular factors regulating skeletal
muscle mitochondria in ALS, muscle samples from patients
with FALS and SALS, as well as the SOD1G93A ALS mouse
model, exhibit a significant reduction in the mRNA and
protein levels of the transcriptional co-activator, peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC-1α), when
compared with age matched control subjects and nerve disease
(ND) control patients (Russell et al., 2012; Thau et al., 2012).
Up regulation of PGC-1α increases mitochondrial biogenesis
and enhances mitochondrial function via the induction and
activation of several nuclear transcription factors, such as nuclear
respiratory factor-1 (NRF-1) (Wu et al., 1999) and estrogen-
related receptor alpha (ERRα) (Schreiber et al., 2004) and several
gene targets including mitofusin-2 (Mfn2) (Cartoni et al., 2005)
and COX subunit IV (COX IV) (Puigserver et al., 1998). PGC-
1α also attenuates muscle atrophy programs (Sandri et al., 2006).
In addition to PGC-1α, several of its downstream effectors of
mitochondrial function, NRF-1, ERRα, and COX IV, are also
down regulated in FALS and SALS patients (Russell et al.,
2012). Additionally, a decrease in PGC-1α in the spinal cord
and motor cortex of post-mortem ALS patients and spinal
cord of end stage ALS mice has also been observed (Thau
et al., 2012). The elevation of PGC-1α has been attempted by
crossing transgenic PGC-1αmice with various SOD1 ALS mouse
models, but with varying results. Overexpression of PGC-1α
in neurons of SOD1G93A ALS mice improved motor function
and survival (Zhao et al., 2011), while overexpressing PGC-
1α in fast-twitch muscles of SOD1G37R (glycine to arginine
mutation at position 37) ALS mice improved skeletal muscle
function and mitochondrial biogenesis, but did not preserve
neurodegeneration or extend survival (Da Cruz et al., 2012).
However, in transgenic SOD1G37R/PGC-1α mice that are born
with elevated PGC-1α levels, the transgenic advantage is lost as
they move from symptomatic to end-stage. By end-stage their
PGC-1α levels are reduced to those of the ALS wild-type mice
(Da Cruz et al., 2012). This suggests the existence of a potent
post-transcriptional regulatory mechanism that reduces PGC-1α
levels in ALS.
MITOCHONDRIAL DYSFUNCTION AND
THE NEUROMUSCULAR JUNCTION
Skeletal muscle fibers from 37 day old pre-symptomatic
SOD1G93A ALS mice have a reduction in mitochondrial inner
membrane potential in the fiber segments proximal to the NMJ
(Zhou et al., 2010). These fiber segments also had greater osmotic
stress-induced Ca(2+) release activity that were confined to
regions of depolarized mitochondria. It is therefore of interest to
investigate if this may contribute to NMJ degeneration. Of note,
the loss of skeletal muscle mitochondrial membrane potential
and disturbed Ca2+ handling in these 37 day old SOD1G93A
ALS mice occurs earlier than defects previously detected in
motor neuron terminals from 47 day old SOD1G93A ALS mice
(Kennel et al., 1996; Fischer et al., 2004). This further supports
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the notion that skeletal muscle plays a direct role in disease on
set and progression. Studies using Sod1(−/−) mice to investigate
the relationship between muscle mass, mitochondrial function
and NMJ degeneration have reported interesting findings.
Global Sod1(−/−) mice have muscle atrophy associated with
a progressive decline in mitochondrial bioenergetics and an
increase in the production of mitochondrial reactive oxygen
species (ROS) (Jang et al., 2010). Interestingly the these global
Sod1(−/−) mice also have an increase in muscle mitochondrial
content near the NMJ. However, these mitochondria have
impaired function that is associated with increased denervation
of the NMJs and fragmented acetylcholine receptors. In contrast,
skeletal muscle specific Sod1(−/−) mice have normal ATP
production and do not exhibit significant muscle atrophy,
NMJ degeneration or increases in oxidative ROS production,
although muscle contractile force is reduced (Zhang et al., 2013).
These results suggest that a loss of Sod1 activity, specific to
skeletal muscle, does not cause mitochondria dysfunction that
is sufficient to activate muscle and NMJ degeneration pathways.
In contrast, whole body loss of Sod1 presents a more dramatic
phenotype where by its central and peripheral ablation may
converge to severely impact skeletal muscle health. While these
studies provide interesting insights into the direct and indirect
roles of Sod1, the direct relevance of Sod1 knock-out mice to ALS
pathology needs to be considered with caution. The mutations in
SOD1 observed in ALS does not result in its ablation, but instead
its accumulation and gain-of-function (Tsuda et al., 1994). The
consequences of SOD1 mutations appears different to Sod1
ablation, especially in skeletal muscle.
As mitochondrial dysfunction is seen as key factor in ALS
pathogenesis, targeted interventions have been used to try
and improve mitochondrial function and calcium handling.
Various approaches used include intrathecal administration of
the immunosuppressant cyclosporine A (Keep et al., 2001),
ablation of the mitochondrial matrix protein cyclophilin D
(Martin et al., 2009; Parone et al., 2013) and treatment with GNX-
4728, a modulator of the mitochondrial permeability transition
pore (Martin et al., 2014). These treatments all improved
mitochondrial function and survival with improvement in
calcium handling (Parone et al., 2013) and NMJ stability (Martin
et al., 2014).
Mice overexpressing uncoupling protein-1 (UCP1) in skeletal
muscle have decreased mitochondrial membrane potential and
respiratory control ratio (Dupuis et al., 2009) that is associated
with muscle atrophy, a shift from a fast to slow muscle fiber
type phenotype and a deterioration in the NMJ; alterations
also observed in ALS mice (Gordon et al., 2010). SOD1G86R
ALS mice crossed with the muscle specific UCP1 transgenic
mice have a more severe disease progression that coincides
with NMJ deterioration. Further evidence linking impaired
mitochondrial functionwithNMJ deterioration comes frommice
manipulated with the ubiquitously expressed mitochondrial-
targeted endonuclease, mito-PstI, that develop double-strand
breaks in their mitochondrial DNA (Wang et al., 2013). These
mice have muscle wasting and reduced locomotor activity
later in life. This coincided with a decline in muscle SC
number and muscle regenerative capacity. NMJ integrity was
also compromised as indicated by impaired acetylcholinesterase
(AChE) activity and development.
While more direct experimental studies are still required to
establish cause and effect there are now several studies that
demonstrate associations between skeletal muscle mitochondrial
dysfunction, SC activation and NMJ stability. It appears that
effective cross talk between mitochondria, SC’s and the NMJ is
required to maintain optimal skeletal muscle size and function
and that an impairment in this signaling may have detrimental
consequences, contributing to an ALS-like phenotype.
microRNA (miRNA) REGULATION IN ALS
SKELETAL MUSCLE
MiRNAs are small, non-coding RNAs that post-transcriptionally
regulate gene expression and inhibit protein translation (Bartel,
2004), although in some instances they can increase gene
expression (Vasudevan et al., 2007). Few studies have investigated
the role of skeletal muscle miRNAs in the regulation of
myogenesis, mitochondrial biogenesis and NMJ innervation in
ALS. Muscle-enriched miRNAs (myomiRs) such as miR-1, miR-
133, and miR-206 regulate SC proliferation and differentiation
in vitro (Chen et al., 2006). miR-1 promotes myogenesis by
inhibiting histone deacetylase 4 (HDAC4), a transcriptional
repressor of muscle gene expression. On the other hand, miR-
133 induces SCs proliferation by repressing serum response
factor (SRF). Similarly, miR-206 increases SC proliferation and
differentiation by repressing Pax3 and Pax7 protein levels (Kim
et al., 2006; Chen et al., 2010; Dey et al., 2011). Additionally,
miR-489 (Dey et al., 2011), miR-27b (Crist et al., 2009), and
miR-181 (Naguibneva et al., 2006) also downregulate Pax7,
Pax3, and homeobox protein Hox-A11, respectively, resulting
in the promotion of SC differentiation. Overexpression of miR-
125b, inhibits myoblast differentiation in culture and muscle
regeneration in mice via its inhibition of IGF-2. miR-128 also
inhibits bovine SC proliferation and myogenic differentiation
via suppressing specificity protein-1 (Sp1) (Dai et al., 2016).
In contrast, inhibition of miR-128 increases Sp1 protein levels
resulting in a suppression of proliferation and an increase
in differentiation. The miR-128/Sp1 regulatory axis influences
myogensis as Sp1 is required to activate MyoD and supresses
cyclin-dependent kinase inhibitor 1A (CDKN1A). In ALS,
SC activation, proliferation and differentiation are in state of
disequilibrium due to the intrinsic stress placed on the skeletal
muscle. Investigating the regulation of these miRNAs and their
known gene targets may provide a better understanding of how
to combat the myogenic perturbations associated with ALS.
In muscle samples from patients with ALS, when compared
with healthy controls, elevated levels of miR-206, miR-23a,
miR-29b, miR-31, and miR-455 was observed (Russell et al.,
2012). miR-1 and 181 levels were elevated, but not statistically
significant; potentially due to the relatively small sample
size. More studies are required to extend and validate these
observations in human ALS muscle. Similarly, in muscle
from SOD1G93A ALS mice increases greater than 2-fold were
observed for several miRNAs, including miR-1, miR-133,
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miR-206, miR-23a, and miR-29a (see online Supplementary
Figure S1 in Williams et al., 2009). Whether the regulation
of these miRNAs is a cause of impaired myogenesis or
an attempt to rescue this process in ALS is presently
unknown.
miR-23a is another miRNA dysregulated in skeletal muscle of
ALS patients. In skeletal muscle from ALS patients, the increase
in miRNA-23a was associated with a decrease in PGC-1α mRNA
and protein level (Russell et al., 2012). miRNA-23a is a direct
inhibitor of PGC-1α in vitro (Russell et al., 2012) and mice over
expressing miR-23a have a reduction in PGC-1α levels (Wada
et al., 2015). In ALS the elevated levels of skeletal muscle miR-
23a may play a role in the dysregulation of skeletal muscle
mitochondria and the NMJ, however this direct relationship has
not yet been investigated.
In SODG93A ALS mice, miR-206 is dramatically upregulated
in skeletal muscle (Williams et al., 2009). It appears that the
upregulation of miR-206 is a stress-related response to the ALS
disease, as ALS mice rendered deficient in miR-206 have an
accelerated disease progression. miR-206 plays a compensatory
role by promoting the regeneration of neuromuscular synapses
and slowing the ALS disease progression. The effect of miR-
206 on NMJ regeneration is partly explained by its regulation
of HDAC4 and FGF signaling. miR-206 also regulates other
SCs markers including connexin 43 (Cx43) (Araya et al., 2005),
utrophin (Utrn), follistatin-like 1 (Fstl-1) (Rosenberg et al.,
2006), and MyoD (Dey et al., 2011; Koning et al., 2012).
miR-206 upregulation in ALS (Williams et al., 2009) may also
be an attempt to positively affect SC activation, proliferation
and differentiation required for myogenesis, as well as assist
with NMJ protection. However, this requires experimental
validation.
CONCLUSION
There is now a large body of evidence supporting the
role of skeletal muscle impairments in the development
and severity of ALS. The dysfunction in skeletal muscle
SC activation, proliferation and differentiation, as well as
mitochondrial function, may synergize to develop a less than
optimal environment for the maintenance of NMJ innervation.
Consequently, this may instigate retrograde signaling through
the NMJ and contribute to the degeneration of motor
neurons. The precise cause of these perturbations are unclear.
From a molecular level, alterations in the transcriptional and
post-translational control of key genes/proteins involved in
myogenesis and mitochondrial biogenesis have been postulated.
Biochemically, impaired Ca2+ handling and ROS removal
may contribute to the development of a toxic muscle milieu.
Importantly, many of these skeletal muscle perturbations,
most notably in the mitochondria and NMJ, occur in the
presymptoimatc stage. These observations suggest that skeletal
muscle plays a direct role in disease on set, progression
and severity. Studies targeting skeletal muscle that are aimed
at understanding the interrelationship between SC activation,
myogenesis, mitochondrial function andNMJ health in ALS,may
contribute to better understanding the disease etiology as well
as its progression. In doing so this research may identify novel
mechanisms contributing to disease on set, as well as novel targets
that may lend themselves to therapeutic manipulation.
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